<DOC>
	<DOCNO>NCT02307604</DOCNO>
	<brief_summary>The SPECTAbrain protocol describe structure screen patient brain tumor efficiently allocate eligible patient relevant therapeutic biomarker-driven clinical trial . Efficiency promote creation clinical database brain tumor patient respective human biological material biobank molecular characterization . The main objective : - Allocate patient clinical trial accord clinical characteristic molecular profile tumor ; - Identify validate new molecularly define subgroups tumor ; - Investigate prevalence novel biomarkers plan future clinical trial ; - Enable exploratory/future research ; - Facilitate establishment quality-assured validated test Central Nervous System ( CNS ) tumor biomarkers ;</brief_summary>
	<brief_title>SPECTAbrain : Screening Patients With Brain Tumors Efficient Clinical Trial Access</brief_title>
	<detailed_description />
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Pathologically confirm newly diagnose primary CNS tumor , focus diffuse glioma grade II , III IV , meningioma patient candidate pharmacotherapy , rare CNS tumor ; Availability adequate Human Biological Material ( HBM ) : FFPE tissue sample primary and/or recurrent tumor and/or metastasis , obtain time surgery biopsy ; minimal amount request detailed HBM guideline . Inclusion sample take recurrence diagnose followup strongly encouraged optional ; At least three month life expectancy ; Written inform consent accord ICH/GCP national/local regulation ; Absence exclusion criterion , active hepatitis B/C HIV , second malignancy , severe organ dysfunction , comorbidities prevent inclusion clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Brain tumor</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Screening</keyword>
</DOC>